Emmanuel Stylianos Antonarakis MD
Genitourinary Oncology
Professor of Medicine (Oncology), University of Minnesota. Director of Translational Research, Masonic Cancer Center.
Join to view full profile
909 Fulton St SEMinneapolis, MN 55455
Phone+1 612-672-6000
Dr. Antonarakis is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010- Johns Hopkins UniversityResidency, Internal Medicine, 2004 - 2007
The University of Wales College of MedicineClass of 2003
Certifications & Licensure
MN State Medical License 2021 - 2027
NH State Medical License 2024 - 2024
MD State Medical License 2007 - 2022
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
- A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer Start of enrollment: 2013 Jan 18
- 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
Publications & Presentations
PubMed
- Long-term outcomes and treatment cessation in patients with response to first-line treatment of metastatic prostate cancer.Monica Meeks, Yasaman Iranmanesh, Hyunsoo Song, Amanda L Blackford, Arya Rasouli
The Oncologist. 2026-10-07 - Clinical and Molecular Profiles of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancers in the Era of Intensified Systemic Therapies.Nadeem Bilani, Jesenia M Perez, Ana M Aparicio, Carolina Colli-Cruz, Cora N Sternberg
Cancer Research Communications. 2026-09-29 - Cardiovascular Risk Triage Schema for Patients With Prostate Cancer Treated With Hormone Therapy.Avirup Guha, Ana Barac, Michael James Ryan, Randala Hamdan, Geeta Devgan
JCO Oncology Practice. 2026-09-28
Journal Articles
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerEmmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
Lectures
- Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analy...2019 ASCO Annual Meeting - 6/1/2019
Other
- Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and EnzalutamideEmmanuel Antonarakis, MD, European Urology
https://www.doximity.com/articles/aa1e6f6d-be80-4fdc-91e9-2ccae3c99bc3
UpToDate, Wolters Kluwer Health - 2013-04-10
Authored Content
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-Resistant Prostate Cancer in the Era of Precision OncologyApril 2018
Press Mentions
BRCA1 Contribution to Prostate Cancer Called into QuestionFebruary 24th, 2025- Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men with Biochemically Recurrent Prostate CancerAugust 21st, 2024
- Study Shows How Novel Immunotherapy Helps Fight High-Risk Prostate Cancer, ET HealthWorldApril 8th, 2023
Grant Support
- Mayo Clinic / University of Minnesota Prostate SPOREMAYO CLINIC ROCHESTER2026–2031
Professional Memberships
- Member
Other Languages
- French, Greek
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
